UK Sickle Cell Disease Disease Landscape

Sickle cell disease is the UK's largest haemoglobinopathy population and the largest in Europe: an estimated 15,000–17,000 patients, concentrated at specialist centres in London (Barts, King's, Imperial, Homerton — roughly 6,000 patients combined), Birmingham Heartlands (roughly 2,000), Manchester, Bristol, and Nottingham. The NHS has screened for SCD and sickle cell trait since 1999, so virtually all UK SCD patients are now diagnosed at birth; roughly 350–500 new SCD births occur annually, reflecting immigration patterns from Sub-Saharan Africa and the Caribbean.

Hydroxycarbamide (hydroxyurea) is recommended for moderate-to-severe disease under the British Society for Haematology's 2018 guideline, generally three or more vaso-occlusive crises per year or significant end-organ damage, within the broader NHS sickle cell care standard set by NICE's CG143 (acute painful episode management) and QS58 (quality standard). A 2022 NHS audit found roughly half of eligible UK patients on hydroxyurea, better than the US (25–30%) but below guideline target, with adherence, fertility concerns in young adults, and prescriber reluctance outside specialist settings cited as barriers. The access picture changed on 16 November 2023, when MHRA granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel, exa-cel), the first CRISPR gene therapy licensed in the UK for sickle cell disease. NICE published TA1044 in February 2025, recommending Casgevy with managed access for severe SCD patients 12 and over who cannot access a matched-donor stem cell transplant; NHS England is planning gene-therapy hubs at 6–8 JACIE-accredited bone-marrow-transplant centres, with budget-impact modelling putting 200–300 eligible severe patients per year against a therapy price exceeding £1.5 million, an annual NHS England exposure of £300–600 million, the largest single rare-disease programme in NHS history. Lyfgenia (lovotibeglogene autotemcel, lovo-cel), bluebird bio's competing gene therapy, is FDA-approved in the US but has no MHRA authorisation or NICE appraisal in the UK and is not part of the current NHS commissioning pathway.

UK sickle cell disease landscape is built from primary NHS and NICE sources, the NHS SCD Programme, NICE guidance CG143/QS58 and TA1044, the British Society for Haematology hydroxycarbamide guideline, MHRA gene-therapy approvals, and NHS England budget-impact and commissioning planning documents, together with UK national registry data, not secondary summaries or unverified estimates.

Key sources: NHS SCD Programme 2023; UK SCD Registry (WISERD); NICE CG143 and QS58; British Society for Haematology hydroxycarbamide guideline, 2018; NHS SCD audit 2022; MHRA Casgevy approval (16 November 2023); NICE TA1044 (Casgevy, February 2025); NHS England SCD gene therapy planning 2024.